Reviewing ACTRIMS 2024
Episode 111, Mar 22, 10:00 AM
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Daniel Ontaneda, MD, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine, sat down to discuss the recently concluded Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. Ontaneda, program committee vice-chair of the meeting, provided insight on a number of notable sessions and discussions that highlighted the recent advances in the MS field. In addition, he talked about the need to innovate clinical trials, ways to tackle progressive MS, and whether drug trials are truly assessing patients at the right time points. Furthermore, he discussed multi-stage trials, the potential role of Bruton tyrosine kinase (BTK) inhibitors, and how this year's meeting differs from previous ones.
Looking for more multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page.
Episode Breakdown:
In this episode, Daniel Ontaneda, MD, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine, sat down to discuss the recently concluded Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. Ontaneda, program committee vice-chair of the meeting, provided insight on a number of notable sessions and discussions that highlighted the recent advances in the MS field. In addition, he talked about the need to innovate clinical trials, ways to tackle progressive MS, and whether drug trials are truly assessing patients at the right time points. Furthermore, he discussed multi-stage trials, the potential role of Bruton tyrosine kinase (BTK) inhibitors, and how this year's meeting differs from previous ones.
Looking for more multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page.
Episode Breakdown:
- 1:05 – Overviewing sessions from ACTRIMS Forum
- 13:10 – Innovating clinical trial design
- 16:15 – 2023 ACTRIMS vs 2024 ACTRIMS
- 20:20 – Neurology News Minute
- 23:30 – Testing combination approaches for progressive MS
- 26:45 – The impact of timing therapeutic interventions
This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
FDA AdComm to Review Investigational Alzheimer Agent Donanemab and Phase 3 Results
Amylyx Mulls Over Pulling AMX0035 Following Disappointing Phase 3 PHOENIX Findings
FDA Issues Complete Response Letter for Long-Acting Form of Glatiramer Acetate for Relapsing Multiple Sclerosis
- Phase 2 PROCEED Trial of PACAP-Targeting Antibody Lu AG09222 in Migraine Announced
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.